7-2-4-3　ⓔ文献

  1. McFarland LV, Surawicz CM, et al: Risk factors for Clostridium difficile carriage and C. difficile–associated diarrhea in a cohort of hospitalized patients. J Infect Dis, 1990; 162: 678–684.

  2. Warny M, Pepin J, et al: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet, 2005; 366: 1079–1084.

  3. 公益社団法人日本化学療法学会・一般社団法人日本感染症学会 CDI診療ガイドライン作成委員会編．Clostridioides(Clostridium)

difficile 感染症診療ガイドライン．2018．http://www.kansensho.or.jp

/guidelines/pdf/guideline_cdi_fc.pdf

  1. Lewis SJ, Heaton KW: Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol, 1997; 32: 920–924.

  2. 小西敏郎：手術後MRSA腸炎とその対策．外科治療，1999; 80: 235–236.

  3. Konishi T, Idezuki Y, et al: Oral vancomydin hydrochloride therapy for postoperative methicillin–cephem–resistant Staphlococcus aureus enteritis. Surg Today, 1997; 27: 826–832.

  4. Okii K, Hiyama E, et al: Molecular epidemiology of enteritis–causing methicillin–resistant Staphylococcus aureus. J Hosp Infect, 2006; 62: 37–43.